Effects of candesartan cilexetil (Candesartan) on diabetic retinopathy in type 1 diabetic patients without retinopathy

Trial Profile

Effects of candesartan cilexetil (Candesartan) on diabetic retinopathy in type 1 diabetic patients without retinopathy

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2014

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Diabetic nephropathies; Diabetic retinopathy; Proteinuria
  • Focus Registrational; Therapeutic Use
  • Acronyms DIRECT; DIRECT-Prevent-1
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jul 2009 Results of a prespecified pooled analysis of the three DIRECT trials (DIRECT-Renal) published in Annals of Internal Medicine.
    • 26 Sep 2008 Results have been published in the Lancet.
    • 11 Sep 2008 Primary endpoint 'Diabetic complications occurrence' has not been met, as reported in a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top